Embed Size (px)
Citation preview
In case of soluble matrices, a hydrogel formed after contact of the matrix with the release medium and drug release occurs either via drug diffusion through a network of capillaries formed between compacted matrix former or/and erosion of the matrix. Dependent on the aqueous drug solubility, one of the mechanisms could dominate or combination of both takes place [1].
Despite that Carbopol 71G is
crosslinked polyacrylic acid and in principles is insoluble, the drug release occurs similarly to the water soluble matrices including erosion [2]. Being a weak acid, Carbopol 71G can interact with weak bases at pH>pKа=6.1. Trimetazidine dihydrochloride as a weak base (pKa1 4.45, pKa2 9.14 [4]) can interact with Carbopol 71G. Therefore, the aim of this work was to investigate the trimetazidine-Carbopol interaction and its effect on drug release from matrix tablet.
TRIMETAZIDINE-CARBOPOL INTERACTION IN THE MATRIX TABLET V. V. Mohylyuk1, 2, L. L. Davtian1, A. M. Dashevskiy2, R. Bodmeier2 1 Shupyk National Medical Academy of Postgraduate Education, Dorohozhyts’ka str. 9, 04112 Kyiv 2 College of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
API: Trimetazidine dihydrochloride (TMZ•2HCl, Sochinaz SA, Switzerland);
matrix former: crosslinked polyacrylic acid (Carbopol 71G, The Lubrizol Corp., USA); filler: lactose monohydrate (Granulac 200, Meggle AG, Germany); glidant: colloidal silicon dioxide (Aerosil 200 Ph, Evonik AG, Germany), lubricant: sodium stearyl fumarate (Pruv, JRS Pharma, Germany). Tablet preparation
Direct compression method was applied to obtain 200 mg biconvex tablets with 8 mm diameter according to the formulation presented in Table 1 using a mixer (Turbula T2F, Willy A. Bachofen AG, Switzerland) and eccentric tablet press (Korsch EKO, Korsch AG, Germany).
Table 1. Tablet composition (%/tablet).
Dissolution test
The drug release from tablets was investigated in a paddle apparatus (Vankel VK 300, Vankel Industries, Edison., NJ, USA) at following conditions: 900 ml of 0.1
N HCl or PBS pH 6.8, 100 rpm, 37°C; (n=3). Samples were withdrawn at predetermined time points, filtered through 0.35 µm filters and measured UV-
spectrophotometrically at =269 nm.
Slow down of release in the release medium with pH 6.8 was due to the interaction of TMZ•2HCl and Carbopol 71G with gel layer formation. This interaction could be used for further retardation. Different release rate and mechanical properties of tablet in different physiological pH could provide
problems for in vitro/in vivo correlation because of unpredictable tablet presence in stomach. Therefore, one of the approaches to achieve this retardation on pH independent manner would be an enteric coating.
CONCLUSION
1. Aulton, M.E., [ed.]. Pharmaceutics: the Science of Dosage Form Design. 2-nd Ed. s.l. : Churchill Livingstone, 2002. pp. 289-305.
2. Lubrizol Advanced Materials, Inc. Pharmaceutical Polymers for Oral Solid Dosage Forms. Technical Data Sheet. 2011, pp. 1-7.
3. Lubrizol Advanced Materials, Inc. Neutralizing Carbopol and Pemulen Polymers in Aqueous and Hydroalcoholic Systems. Technical Data Sheet. 2009, 237, pp. 1-3.
4. Reymond, F, et al. The pH-partition profile of the anti-ischemic drug trimetazidine may explain its reduction of intracellular acidosis. Pharm Res. May 1999, Vol. 16, 5, pp. 616-624.
REFERENCES
In this medium, Carbopol 71G was not ionised and no interaction with TMZ•2HCl occurred. The release of freely soluble drug from swollen tablets was driven by diffusion and was relatively fast (Fig. 1). In pH 6.8, approx. 80 % of carboxyl groups of Carbopol 71G and almost all tertiary amine groups of TMZ were ionised and can interact with each other forming salt in a form of erodible gel layer (Figs. 3 B, 2 D, 3) on the surface of the tablet. Tablets containing TMZ did not swell in this medium in contrast to drug- free tablets (Fig. 2).
Figure 1. Effect of medium pH on
drug release.
TMZ•2HCl release from matrix tablets at pH 1 was much faster then at pH 6.8 (Fig. 1) or slowed down upon medium change from pH 1 to pH 6.8 after 2 h. Since the solubility of Granulac 200 and TMZ•2HCl is relatively pH independent in the range 1-6.8, the ionic interaction between positively charged TMZ and negatively charged Carbopol 71G could be a reason for slower drug release.
Table 2. Aqueous solubility of
TMZ•2HCl and Granulac 200.
The swelling/erosion behavior in acidic dissolution medium of Carbopol 71G containing tablets was not affected by presence of TMZ•2HCl (Fig. 2).
Figure 2. Matrix tablets behaviour
during dissolution test.
Formulation F1 F2
TMZ•2HCl 17.5 --
Granulac 200 31.3 48.8
Carbopol 71G 50
Aerosil 200 Ph. and Pruv 0.2 and 1.0
Compounds
Solubility (mg/ml) at pH
corresponding to
acidic neutral
TMZ•2HCl 620 (pH 0.6) 340 (pH 6.7)
Granulac 200 210 (pH 0.9) 210 (pH 6.5)
pH 1 2 h at pH 1,
17 h at H 6.8 pH 6.8
Time F1 F2 F1 F2 F1 F2
2 h
5 h
19 h
Figure 3. TMZ•2HCl containing matrix
tablet after 5 h in dissolution medium
pH 6.8: A) whole tablet, B) separated
gel layer, C) separated gel core,
D) cross-section.
The increased swelling and viscosity of ionised Carbopol 71G in the dissolution medium with pH 6.8 is well known phenomenon [3]. However, due to interaction with ionized TMZ, drug containing tablets did not swell but rather eroded (Fig. 2). pH measurement of different regions of tablet cross-section after 5 h of dissolution test in phosphate buffer pH 6.8 showed a pH gradient inside of tablets. The pH decreased from approx. 7 on the surface
to 2-3 in the centre of the tablet (Fig. 3 D). The pH 5-7 in outer layer corresponds to ionized state of Carbopol 71G and TMZ•2HCl, where the interaction was possible. The interaction of Carbopol 71G and TMZ in the outer layer could be used for retardation of drug release.
Lisbon Portugal
31 March to 3 April 2014
9th World Meeting on Pharmaceutics,Biopharmaceutics and Pharmaceutical Technology
In combination with
www.worldmeeting.org
9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical TechnologyLisbon, Portugal, 31 March to 3
April 2014 3
Lisbon9th
World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
Lisbon Portugal
31 March to 3 April 2014
Lisboa Congress Centre
Address: Praça das Indústrias , 1300-307 Lisbon, Portugal
Chairs and Committees
Conference ChairJoão F. Pinto, Lisbon, Portugal
Co-Chairs of the Conference Franco Alhaique, Rome, Italy
Jörg Breitkreutz, Düsseldorf, Germany
Jürgen Siepmann, Lille, France
Programme Committee ChairJörg Breitkreutz, Düsseldorf, Germany
Programme CommitteeMarco Adami, Italy
Anna Maria Fadda, Italy
Juan Manuel Irache, Spain
Vincent Jannin, France
Karsten Mäder, Germany
Andreas Rummelt, Switzerland
Local OrganiserJoão F. Pinto, Lisbon, Portugal
International Advisory BoardMiloslava Rabiškova, Czech Republic
Rudolf Kessler, Germany
Wieland Wolf, Germany
Peep Veski, Estonia
Catherine Tuleu, United Kingdom
Leena Peltonen, Finland
Sven Stegemann, Germany
Stephan Buchmann, Switzerland
Piroska Szabó-Révész, Hungary
Lilian Azzopardi, Malta
Renata Jachowicz, Poland
Rosa Jiménez-Castellanos, Spain
Gerrit Borchard, Switzerland
Bill Dawson, United Kingdom
Valerie Andreev, Bulgaria
Véronique Préat, Belgium
Sharon Pichon, USA
9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical TechnologyLisbon, Portugal, 31 March to 3
April 2014 5
9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical TechnologyLisbon, Portugal, 31 March to 3
April 2014 23
Posters
Tuesday, 01 April 2014
PostersExhibited continuously from 9:00 to 17:00, with special sessions from 12:45 to 15:00. The number indicates the number displayed on the poster panel.
Nanoparticles: Lipid nanocarriers
1 Enhanced in vitro antileukemic activity of all-trans retinoic acid-loaded solid lipidnanoparticlesG. Carneiro, E. Luiz Silva, C. dos Santos Giuberti, D. Assis Gomes, M. Cristina de Oliveira andL. Antônio Miranda Ferreira
2 Calorimetric studies of lipid effects on bemotrizinol loading into nanostructuredlipid carriers (NLC)L. Montenegro, M. Sarpietro, M. Accolla, R. Cavallo, G. Puglisi and F. Castelli
3 LOWERING OF INTRAOCULAR PRESSURE BY MELATONIN LOADED IN CATIONICSOLID LIPID NANOPARTICLES A. Leonardi, C. Bucolo, S. Salomone, F. Drago, G. Puglisi and R. Pignatello
4 Lipid nanoparticle inclusion prevents capsaicin-induced TRPV1 defunctionalizationC. Puglia, M. Zammataro, A. Offerta, T. Musumeci, B. Ruozi, G. Puglisi, F. Bonina and S. Chiechio
5 Design of solid lipid nanoparticles for caffeine topical administrationC. Puglia, A. Offerta, G. Puglisi and F. Bonina
6 ANTIALZHEIMER CODRUG LOADED IN SOLID LIPID NANOPARTICLESL. Marinelli, P. Sozio, L. Cerasa, H. Turkez and A. Di Stefano
7 NANOSTRUCTURED LIPID CARRIERS AS A STRATEGY TO IMPROVE IN VITRO SCHISTOSOMIASIS ACTIVITY OF PRAZIQUANTELF. Kolenyak-Santos, R. Nunes de Oliveira, A. Ribeiro de Souza, S. Marques Allegretti, M. Chaud andM. Daflon Gremião
8 Asymmetrical flow field-flow fractionation in combination with inline-coupled dynamiclight scattering techniques for analysis of PEGylationC. John and K. Langer
9 Effect of autoclaving on the properties of lipid nanodispersions:A flow field-flow fractionation studyA. Arnold, K. Göke, E. Roese, H. Bunjes and J. Kuntsche
10 Composition dependent toxicity of lipid nanocapsules in A549 alveolar epithelial cellsA. Umerska and P. Saulnier
92 The Impact of Different Polymers on the Mechanism of Dissolution Enhancement andStorage Stability of Solid Dispersions Prepared via HMEM. Pina, M. Zhao, J. Pinto, J. Sousa and D. Craig
Controlled drug delivery: Pellets & tablets
93 Pellets with controlled release of sugar for hypoglycemia prevention in diabetesJ. Muselík, A. Franc, D. Sabadková and D. Neumann
94 Drug release rate prediction for pellets coated with ethylcellulose filmsK. Martin, W. Mathias and C. Mesut
95 Development of a sustained released dosage form for phenylephrine hydrochlorideusing Solid Lipid PelletsJ. Vertommen and H. Benameur
96 Mini-tablets versus pellets as promising multiparticulate modified release delivery systemsfor highly soluble drugsD. Gaber, N. Nafee and O. Abd Allah
97 Elaboration of L-arginine pellets and their effect on ovulation rate, prolificacy, and VEGFconcentrations in sheep serum after their supplementationZ. Sánchez, J. Ruíz de Chávez, A. Guzmán, A. Rosales, H. Sandoval and L. Melgoza
98 Evaluation of glucose release from the coated pellets with different parameters A. Franc, J. Muselík, D. Neumann, D. Sabadkové and I. Minaříková
99 Characterization of pellets coated with cellulose acetate butyrate R. Ali and R. Bodmeier
100 Development of non-effervescent floating matrix tablet using ammonium carbonateas sublimation substanceS. Sungthongjeen, W. Kriangkrai, P. Sriamornsak and S. Puttipipatkhachorn
101 Development and in vitro evaluation of enteric press-coated tabletsS. Sungthongjeen, S. Wiriyajaree, J. Surusmo, J. Wiwatmanatkul, T. Sirakittiworapongand S. Puttipipatkhachorn
102 Segregated delivery of rifampicin and isoniazid from fixed dose combinations bilayertablets for the treatment of tuberculosisM. Lopes, B. Abrahim-Vieira, A. Silva, L. Silva, H. Castro, F. Veiga, C. Rodrigues, A. Ribeiro,V. Sousa and L. Cabral
103 TRIMETAZIDINE-CARBOPOL INTERACTION IN THE MATRIX TABLETV. Mohylyuk, L. Davtian, A. Dashevskiy and R. Bodmeier
104 Application of Hydroxypropyl Cellulose - Super Fine Powder (HPC-SSL-SFP) to“Tablet Hardness Enhancer” for Hydrophilic Matrix FormulationN. Kuwada, B. Ehlig, K. Sugisawa and S. Tsue
105 Release of Tramadol Hydrochloride from solid drug formsK. Myslikova, A. Komersova and V. Lochar
106 In vivo evaluation of gastric motility of floating tablets by AC BiosusceptometryP. Ferrari, D. Grossklauss, F. Paixão, U. Andreis and J. Miranda
107 Impact of the addition of anti-tacking agents on properties of effervescent floating tabletsW. Kriangkrai, S. Puttipipatkhachorn, P. Sriamornsak, T. Pongjanyakul and S. Sungthongjeen
9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology46 Lisbon, Portugal, 31 March to 3 April 2014
9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical TechnologyLisbon, Portugal, 31 March to 3
April 2014 81
International Exhibition for R & D31 March to 3 April 2014
Lisbon, Portugal
LisbonPortugal, 30 March to 03 April 2014
Programme at a glance
We thank our sponsors:
4 days PBP World Meeting means
– 44 invited speakers from industry and academia
– 66 short lectures on hot topics
– More than 900 scientific poster presentations
– Industry exhibition ResearchPharm®
– A social programme to remember
For meeting updates please visit www.worldmeeting.org and www.researchpharm.org
Monday, 31 March 2014
13:00 Opening ceremony and welcome address
Portuguese University and Government Representatives Jörg Breitkreutz Franco Alhaique Jürgen Siepmann João Pinto
14:30 Keynote lectures
Horizon 2020 - The European research funding programme Maria da Graça Carvalho, European Commission, Belgium
Industry trends towards 2020 Guy Villax, Hovione, Portugal
15:30 Coffee Break
16:00 Hot Topics
Drug Counterfeiting Frédéric Bourgeois, Sanofi, France
Opportunities and challenges in strategical outsourcing Hans Lindner, Bayer Pharma, Germany Jean Cuiné, NextPharma, United Kingdom
18:00 Welcome reception
Pavilion 4 and Pavilion 5 Auditorium I Auditorium VI Auditorium VII Auditorium VIII
Poster Sessions and ResearchPharm
Symposium:Solid Dosage Forms
Short lectures: Protein &
Nucleotide Formulations
Symposium:
Advanced Analytics
Short lectures: Dermal and
Transdermal Delivery
Nanoparticles: Lipid Nanocarrier
Preformulation: Processes
Oral Delivery: Tabletts and extrusion
Controlled Drug Delivery: Polymers
Pharmaceutical Manufacturingand Engineering
Advanced Drug Delivery systems
Dermal and Transdermal Delivery
Protein and gene delivery
IVIVC
Bioavalaibility and Absorption En-hancement
09:00 – 17:00; all day
Oral controlled drug deliveryC. von Corswant
Advances in controlleddrug delivey from an aca-demic perspectiveR. Bettini
Biopharmaceutical perfor-mance assessment of Soliddosage formsX. Pepin
Physicochemical and biolo-gical studies of cationic na-noemulsions as deliverysystems for antimalarial oli-gonucleotidesF. Bruxel
Accelerated FormulationStudies for Frozen Storageof ProteinsM. Rosa
Controlled nucleation com-bined with aggressivefreeze-drying of highlyconcentrated protein for-mulationsI. Konrad
MicroScale Thermophoresis(MST) for mAb Develop-ment and FormulationR. Wanner
Chitosan-based nanogelsfor the cellular delivery ofnucleotides and nucleotideanaloguesH. Hillaireau
Comparison of three nano-vaccine formulations fortheir potential to induceand enhance immune re-sponses against m. tuber-culosisJ. Poecheim
Advanced synchrotron-basedimagining techniques to sup-port the formulation, maufac-turing processes and evaluationof drug effectsJ. Doucet
In vivo imaging techniquesC. Wilson
Scanning white light interfero-metry (SWLI)N. Sandler
New insights into establish-ment and analysis of an impro-ved human in vitro woundmodelM. Windbergs
Ex vivo and in vivo evaluationof the efficiency of calixareneformulations for the treatmentof superficial wounds contami-nated by uraniumS. Grivés
Tactile perception of topicalformulationL. Ringstad
Mometasone Furoate - loadedcold processed oil-in-wateremulsions: in vitro and in vivostudiesS. Raposo
Ultrasmall NLC – improved der-mal delivery of coenzyme Q10C. M. Keck
Characterization and in vitroskin penetration study of nico-tinamide microemulsionP. Boonme
11:45 Auditorium I Plenary lecture: Nanomedicines, Alexander ‘Sasha’ Kabanov
Poster Sessions and ResearchPharm
Symposium:Coated Dosage Forms
Short lectures: Pharmacoki-
netics & IVIV Correlations
Symposium: Protein
Formulation & Aggregation
Short lectures: Liposomes &
other advanced DDS
Nanoparticles: Lipid Nanocarrier
Preformulation: Processes
Oral Delivery: Tabletts and extrusion
Controlled Drug Delivery: Polymers
Pharmaceutical Manufacturingand Engineering
Advanced Drug Delivery systems
Dermal and Transdermal Delivery
Protein and gene delivery
IVIVC
Bioavalaibility and Absorption En-
hancement
09:00 – 17:00; all day
QbD and PAT tools for filmcoatingA. Funke
GIT DeliveryA. Basit
Coating of solid dosageformsC. Riedel
Studying distribution andabsorption processes afterintramuscular injectionusing LC-MS/MS and MRIM. Probst
Delivering crushed tabletsusing thickened fluids: sali-vary paracetamol concen-trations indicate an effecton absorptionC. Radhakrishnan
Intragastric volume and fatcontent changes after in-take of high-caloric, high-fat breakfast in healthyhuman subjects investiga-ted by MRIM. Koziolek
Zein nanoparticles as car-riers for the oral bioavaila-bility of resveratrolR. Peñalva
Per-oral itraconazole nano-crystal formulations: supe-rior in vitro dissolution notfully reflected to bioavaila-bilityA. Sarnes
Smart ways to overcomethe solubility hurdle andreduce time to market: en-abling formualtion techno-logies and In-Vitro/In-Vivocase studiesG. Filipcsei
Freeze-drying of proteins: Qua-lity by Design (QbD) in formula-tion and process designM. Pikal
Formulation Development ofnew anti-body scaffoldsS. Huille
Vaccine Design: Lyophilizationand deliveryJ.-P. Amorij
Liposomal post-insertion featu-res of HA-DPPE conjugateD. Cosco
Microcontainers, an innovativeoral drug delivery system forpoorly soluble drugsL. Hagner Nielsen
Cross-linked chitosan/liposomehybrid systems for colon-targe-ted delivery of quercetinC. Caddeo
Multimodal Theranostics of Tu-moral Cells with Hybrid Nano-particlesP. Taboada
How to develop a Self-Emulsify-ing Lipid Formulation for BCSclass II drugs?V. Jannin
Polysaccharide Nanohydrogelsas Drug CarriersP. Matricardi
Tuesday, 1 April 2014
09:0
009:2
0 0
9:4
0 1
0:0
010:2
0 1
0:4
015:0
0 1
5:2
0 1
5:4
0 1
6:0
0 1
6:2
0 1
6:4
0
11:30 Auditorium I APV Awards
Pavilion 4 and Pavilion 5 Auditorium I Auditorium VI Auditorium VII Auditorium VIII
Poster Sessions and ResearchPharm
Symposium:
Nanoparticles & Vesicles
Symposium:
Continuous Manufacturing
Symposium:
Patient-Centred Medicines
Short lectures:
Controlled Drug Delivery
Nanoparticles: Polymers
Prefomulation: Tableteing and dissolution
Oral Drug Delivery: Films and emulsions
Controlled Durg Delivery: pellets and tabletts
Pharmaceutical Manufacturingand Engineering
Advanced Drug Delivery Systems
Physical Pharmacy
Cellular drug transport
Quality Assurance
Regulatory Affairs
PAT and analytics
09:00 – 17:00; all day
Liposomal drug delivery sy-stems: From concept to clini-cal applicationsY. Perrie
Nanosuspension techno-logy: A versatile drug deli-very platformR. Cavalli
Nanoparticle design anddrug deliveryP. Hammond
Continuous wet granula-tion process including QbD& PATM. Wunderlich
Melt Extrusion Technolgoy:Case studiesM. A. Repka
Comminutive Granulation -Continuous Manufacturingof Hot-Melt-Extruded Pel-letsR. K. Mürb
New guideline ”Quality of paed-iatric medicines”: Scientific evi-dence, key aspects and lessonslearnedD. van Riet-Nahles
Patient-centric drug formula-tion principlesR. Becker
Formulation and packagingconsiderations in geriatric me-dicinesT. Shreeves
Novel polysaccharide-baseddrug delivery systems targetingthe inflamed colon: Proof ofconcept in vivoY. Karrout
Development of Sustained andPulsatile Release Co -ExtrusionFormulations for Individual Do-singE. J. Laukamp
Laminar co-extrudates manu-factured at room temperatureand in the absence of solventsfor the delivery of drugs at dif-ferent release ratesG. Oliveira
Gabapentine and Flurbiprofenfixed-dose combination pro-duct: In Vitro and In Vivo drugrelease studiesA. Rossi
Double hydrophilic block copo-lymer based-micelles as vectorsto engineer tolerogenic dendri-tic cells A. Aubert-Pouëssel
Oil-cyclodextrin based beadsfor oral delivery of poorly-solu-ble drugsA. Bochot
11:45 Auditotium I Plenary lecture: Personalized Medicine - Facts and Fiction, Susanne Arbogast
Poster Sessions and ResearchPharm
Symposium:
Tissue Engineering & ATMP
Short lectures:Preformulation & PhysicalPharmaceutics
Symposium:
Green & Sustainable Pharma
Short lectures:
Advanced Analytics
Nanoparticles: Polymers
Prefomulation: Tableteing and dissolution
Oral Drug Delivery: Films and emulsions
Controlled Durg Delivery: pellets and tabletts
Pharmaceutical Manufacturingand Engineering
Advanced Drug Delivery Systems
Physical Pharmacy
Cellular drug transport
Quality Assurance
Regulatory Affairs
PAT and analytics
09:00 – 17:00; all day
Development and manu-facturing of Advanced The-rapy Medicinal Products(ATMP)M. L. Nolli
Recent advances in tissueengineeringR. L. Reis
Biomaterials as TherapeuticCancer VaccinesD. J. Mooney
Prediction of physical stabi-lity of amorphous drugsfrom molecular mobilitystudiesM. Paluch
Nanoformulated itracona-zole prepared by variousspinning methodsZ. Nagy
ToF-SIMS analysis of hydro-lysed acetyl salicylic acidprinted as a microarrayusing ink-jet printingM. Algahtani
General understanding ofphysical stability of phar-maceutical glassesK. Kawakami
Highly tortuous scaffoldsproduced using vacuum-in-duced directional freezingS. Wiedemann
The truncated spheremodel with Voronoi exten-sion enables simulations ofconfined powder compres-sion at large strainsA.-S. Persson
Developing bio- and chemo-ca-talytic technology for API syn-thesisJ. Whittall
Industry case study: Energy andresource saving pharmaceuticalmanufacturingH. Krasowski
Green nanotechnology - A su-stainable source towards thegeneration of new biopharma-ceuticalsK. V. Katti
Statistical process monitoringof a continuous pharmaceuticaltwin screw granulation anddrying processA. F. Tavares da Silva
Correlation between in-lineRaman spectroscopy and spatialfiltering velocimetry for parti-cle size evaluation in fluidizedbed coating processesF. Folttmann
Prediction of the influence ofsupersaturation and precipita-tion on in-vivo absorption of aweak base – application of a bi-phasic dissolution modelK. Frank
Noninvasive in vivo Monitoringof in situ implants by ESR, mul-tispectral optical Imaging andBT-NMRK. Mäder
PAT application in formulationtechnologiesH. Pataki
Coherent anti-Stokes Ramanscattering (CARS) microscopyproviding in depth imaging ofdrug loaded mesoporous MCM-41 silicaA. Fussel
Wednesday, 2 April 2014
09:0
009:2
0 0
9:4
0 1
0:0
0 1
0:2
0 1
0:4
015:0
0 1
5:2
0 1
5:4
0 1
6:0
0 1
6:2
0 1
6:4
0
11:30 Auditorium I EJPB Awards
Pavilion 4 and Pavilion 5 Auditorium I Auditorium VI Auditorium VII Auditorium VIII
Poster Sessions and ResearchPharm
Short lectures:
Nanoparticles
Short lectures:
Site-specific drug delivery
Symposium:
Generics & Biosimilars
Symposium:
Pharmaceutical Engineering
Nanoparticles: Liposomes and nano supspension
Preformualtion: Excipient
Oral Delivery
Controlled Drug Delivery
Pharmaceutical Manufacturingand Engineering
Advanced Drug Delivery Systems
Green and Sustainable Pharma
Pulmonary and nasal delivery
Pediatric Drug Delivery
Starting Materials
Buccal Drug Delivery
Parenteral Delivery
Stability Testing
Advanced Therapy Medicinal Products
Miscellaneous
09:00 – 17:00; all day
Tumor delivery performancestudy of lipid nanocapsulesthrough FRET imagingA.-L. Lainé
PEGylation of non-sphericalparticles and its influence onphagocytosisR. Mathaes
Passive, active and magnetictargeting of multifunctionalnanoparticles for therano-stic applicationsN. Schleich
Dapivirine-loaded polymericnanoparticles for the pre-vention of vaginal HIV trans-missionJ. das Neves
Successful delivery of itra-conazole loaded poly(bu-tylcyanoacrylate)nanospheres into the brainA. Curic
Anti-Abeta antibody deco-rated nanoparticles correctmemory defect in Alzhei-mer’s disease animal modelK. Andrieux
Advantages of a novelwater-soluble CyclosporineA prodrug for ocular appli-cation: Improved availabi-lity and reduced sideeffectsM. Rodriguez-Aller
Direct nose-to-brain deli-very of carbamazepineafter intranasal administra-tion to miceA. Serralheiro
Lung deposition pattern ofa spray-dried powder inlive mice using the Penn-CenturyTM DP-4M Insuffla-torW. Tonnis
pH-responsive Mannan-modified P(HEMA-co-MAA)Nano-hydrogel Carriers forOral Vaccine DeliveryM. Durán-Lobato
Pharmacokinetic and phar-macodynamic study of Pa-clitaxel-loaded lipidnanocapsules after iv andoral administration in rats,on Taxol® resistant tumorA.-C. Groo
A new dissolution methodfor orodispersible films andminitabletsR. Krampe
Branded generics in emergingmarkets J. Figueiredo
Biosimilars, an opportunity anda challenge for the generic’s in-dustryJ. Maset
Biosimilars or Biobetters? Les-sons learned form the filgras-tim portfolio H. Allgaier
The role of pharmaceutical en-gineering in product develop-mentJ.-R. Authelin
Planning and constrution of anew plant for parenteralsA. Graser
From science to biopharmaceu-tical manufacturingD. Estape
11:45 Auditorium I Plenary lecture: Overcoming drug biological barriers: from the cell membrane to the mucosa, Maria José Alonso
Poster Sessions and ResearchPharm
Short lectures:
Oral Drug Delivery
Short lectures: Pharmaceu-
tical Engineering &
Green Manufacturing
Symposium:
Skin, Nose & Lung Delivery
Symposium:
Poorly Soluble Drugs
Nanoparticles: Liposomes and nano supspension
Preformualtion: Excipient
Oral Delivery
Controlled Drug Delivery
Pharmaceutical Manufacturingand Engineering
Advanced Drug Delivery Systems
Green and Sustainable Pharma
Pulmonary and nasal delivery
Pediatric Drug Delivery
Starting Materials
Buccal Drug Delivery
Parenteral Delivery
Stability Testing
Advanced Therapy Medicinal Products
Miscellaneous
09:00 – 17:00; all day
Taste-masked ibuprofenmicropellets using an inno-vative spouted bed conti-nuous pelletizingtechnologyM. Guhmann
A new class of polymers toproduce high-dosed sustai-ned-release oral drug for-mulations via hot meltextrusion: PolyurethanesB. Claeys
Evaluation of injectionmolding for the manufac-turing of immediate re-lease (IR) tabletsA. Melocchi
Prilling as ManufacturingTechnique for Lipid/PEGMultiparticulates for Fixed-Dose CombinationsA. Vervaeck
Hard fat as binder forchild-appropriate, taste im-proved minitabletsC. Eckert
Childrens’ preferences fortablets based on size,shape and colourH. Batchelor
A user-friendly model forspray drying to aid phar-maceutical product deve-lopmentN. Grasmeijer
Critical evaluation of rootcauses of the reduced com-pactability after roll com-paction/dry granulationJ. Mosig
Development of a Continu-ous Wet Granulation Pro-cess by UnderstandingGranule PropertiesA. Birkmire
Improving the uniformityof an active coating pro-cess by DEM simulationsand experimental dataG. Toschkoff
Green re-design of API pro-duction supported by LifeCycle AssessmentD. Kralisch
Ecological Assessment ofPharmaceutical ProductionProcesses in Multi ProductPlantsS. Scholl
Drug Delivery into and throughthe skinR. Guy
Advances in pulmonary drugdeliveryK. Amighi
Advances in intranasal drug de-liverySpeaker tbc
Intestinal absorption studies (invitro - ex vivo - in situ)P. Augustijns
CyclodextrinsT. Loftsson
NanocrystalsJ. Möschwitzer
Thursday, 3 April 2014
09:0
009:2
0 0
9:4
0 1
0:0
0 1
0:2
0 1
0:4
015:0
0 1
5:2
0 1
5:4
0 1
6:0
0 1
6:2
0 1
6:4
0
11:30 Auditorium I JDDST Awards
